Clinical Trial

A Study Evaluating APG777 in Atopic Dermatitis

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants randomized in Part A are not permitted to participate in Part B.
Protocol Amendment History 31 amendments
This ClinicalTrials.gov record has been amended 31 times since 2024-04-29; most recent amendment 2026-07-21.
Status change: Recruiting → Active, Not Recruiting 2025-12-15
Trial Details
NCT Number NCT06395948
Lead Sponsor Apogee Therapeutics, Inc.
Conditions Atopic Dermatitis
Enrollment 470 participants
Start Date 2024-04-29
Primary Completion 2026-11 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-22